Coverage window: August 17-23, 2026
A randomized trial of iPSC-derived heart cells leads this week's issue. Twenty people with advanced ischemic heart failure were followed for a year after bypass surgery, with half also receiving 200 million cardiomyocytes. The study reported encouraging changes in walking distance and myocardial perfusion, alongside ventricular rhythm disturbances that will influence how the next trial is designed.
Three new or updated clinical records extend the picture into Parkinson's disease, premature ovarian insufficiency, and diabetic kidney disease. The laboratory papers take on equally practical problems: removing residual pluripotent cells, keeping grafts alive as sheets, and persuading replacement airway cells to form a working epithelium.
1. The first randomized iPSC-cardiomyocyte trial reports one-year results
Full analysis: HEAL-CHF Puts iPSC Heart Repair Through a Randomized Human Test
Primary sources:
- https://www.nature.com/articles/s41591-026-04605-1
- https://www.researchsquare.com/article/rs-7414031/v1
- https://clinicaltrials.gov/study/NCT03763136
The HEAL-CHF trial enrolled 20 people with advanced ischemic heart failure. All underwent coronary artery bypass surgery; ten were also given 200 million allogeneic iPSC-derived cardiomyocytes through injections around the infarcted area. Treatment allocation was open, while outcome assessors were blinded.
No sustained ventricular arrhythmia occurred during the prespecified one-to-six-month primary window, and imaging found no tumors at 12 months. Rhythm disturbances were still prominent. Every cell-treated participant developed accelerated idioventricular rhythm soon after dosing, and two experienced clinically significant ventricular tachycardia that required cardioversion. Both events resolved.
At one year, the cell group showed larger gains in six-minute walking distance, myocardial perfusion, and wall thickening. The groups did not differ significantly in left-ventricular ejection fraction, ventricular volumes, scar size, heart-failure class, or quality-of-life score. With ten patients per arm, bypass surgery in both groups, no sham injection, and a baseline perfusion imbalance, this is an early safety trial with exploratory signs of benefit. It gives the field a human result worth building on and an arrhythmia problem that the next study must address directly.
2. UCSD's CT1-DAP001 Parkinson study remains open for recruitment
Primary sources:
- https://clinicaltrials.gov/study/NCT06482268
- https://www.cirm.ca.gov/cirm-trial/transplantation-of-human-ips-cell-derived-dopaminergic-progenitors-ct1-dap001-for-parkinsons-disease-phase-i-ii/
The ClinicalTrials.gov record for CT1-DAP001 was updated on August 17 and remains listed as recruiting at the University of California, San Diego. Seven people with Parkinson's disease are expected to receive iPSC-derived dopaminergic progenitors in both putamina, approximately 4.2 to 5.4 million cells per side.
This is an open-label, uncontrolled study with 24 months of follow-up. Adverse events and graft expansion are the primary measures; PET imaging and clinical assessments provide the exploratory readouts. Recruitment rather than a result is the news here. The small study should reveal whether the product, stereotactic delivery, and postoperative follow-up can be carried through safely in the United States.
3. A new ovarian-insufficiency study separates dose finding from placebo control
Primary source: https://clinicaltrials.gov/study/NCT07775391
Shenzhen Wingor Biotechnology posted a Phase I/IIa umbilical-cord MSC trial for premature ovarian insufficiency on August 20. The Phase I portion uses three ascending-dose cohorts and a single intravenous infusion. Its first task is to follow adverse events for 48 weeks.
The Phase IIa portion changes the design. Fifty participants are planned across two cell doses and a placebo group, with three infusions and double-blind assessment. The primary measures at week 24 are follicle-stimulating hormone, estradiol, and anti-Mullerian hormone. Those markers can show a biological change in ovarian function, but the study does not use pregnancy or live birth as a primary endpoint. That distinction will matter if early results are later presented as fertility restoration.
4. Diabetic kidney disease gets a nine-infusion hUC-MSC protocol
Primary source: https://clinicaltrials.gov/study/NCT07769671
A second hUC-MSC record, first posted August 18, plans to enroll 49 people with type 2 diabetic nephropathy at the First People's Hospital of Changzhou. The study is not yet recruiting. Phase I will examine three doses, followed by a randomized Phase IIa comparison between MSCs plus standard treatment and standard treatment alone.
The treatment schedule is substantial: three six-week cycles, each containing three intravenous infusions. The study is open-label, and its main Phase IIa response measure combines changes in proteinuria and estimated glomerular filtration rate six months after treatment. A standard-care control makes those changes interpretable, although the absence of masking leaves room for bias in clinical management and symptom assessment.
5. An hESC-derived stromal-cell product goes through a 52-week safety package
Primary source: https://pmc.ncbi.nlm.nih.gov/articles/PMC13484282/
Researchers at Mirae Cell Bio reported the preclinical safety work behind MR-MC-01, a clinical-grade multipotent mesenchymal cell product derived from a human embryonic stem-cell line for interstitial cystitis. The paper covers three manufactured lots and tests cell identity, genomic stability, residual pluripotency, toxicity, tumor formation, and biodistribution.
The final product had no detectable OCT3/4, TRA-1-60, TRA-1-81, or NANOG signal within the assays used. Immunodeficient mice developed no tumors during 52 weeks of follow-up, and human-cell DNA was no longer detected in major organs after ten days. In a separate spiking experiment, teratomas appeared when undifferentiated hESCs exceeded one percent of the injected population.
These experiments do not tell us whether MR-MC-01 will help patients with bladder pain or urinary symptoms. They show the work required before an hESC-derived product can enter that question: several manufacturing lots, assays for unwanted starting cells, deliberate tumor testing, and long observation after local delivery.
6. iPSC-derived mesenchymal progenitors survive as vascularized cell sheets in mice
Primary source: https://pmc.ncbi.nlm.nih.gov/articles/PMC13486853/
An iScience study assembled human iPSC-derived mesenchymal progenitors into intact sheets and transplanted them beneath the skin of immunocompetent mice. The grafts formed vascularized tissue-like structures and remained detectable for at least 50 days. Fibroblast sheets used for comparison attracted more inflammation and disappeared within a week.
The human sheets expressed anti-inflammatory mediators and contained stromal, vascular-associated, and adipocyte-like components. Composite sheets also improved drainage in a mouse lymphedema model, although that experiment could not isolate the contribution of the iPSC-derived progenitors from the added lymphatic endothelial cells.
Keeping transplanted cells together with their extracellular matrix may solve some of the loss seen after cell suspension delivery. Here it worked at a subcutaneous site in mice. The study did not perform complete lineage tracing, and a xenograft under the skin cannot establish how the same sheets would behave in a human target organ.
7. Airway basal cells rebuild function in culture before the experiment moves in vivo
Full analysis: Airway Basal Cells Rebuild a Working Ferret Epithelium in Culture
Primary source: https://insight.jci.org/articles/view/206375
A JCI Insight research letter tested whether expanded airway basal cells could repopulate an injured ferret epithelium. In cystic-fibrosis G551D air-liquid-interface cultures, transplanted wild-type cells occupied about 77 percent of the epithelium after four weeks and restored CFTR-dependent electrical current and mucociliary transport.
The team then moved to excised wild-type ferret tracheae. Three weeks after transplantation, donor cells made up roughly 30 percent of the surface epithelium and had formed ciliated, secretory, and basal cell types. The tissue retained CFTR-dependent ion transport and ciliary activity.
The two experiments answer different questions. Disease-function rescue occurred in culture; engraftment and multilineage differentiation were shown in excised healthy trachea. A living animal will add immune clearance, mucus, airflow, delivery, and safety constraints that neither system can reproduce. Still, the work defines a measurable route from basal-cell implantation to a functioning airway lining.